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Cystic fibrosis is a monogen-
ic disease that deranges multiple systems of ion trans-
port in the airways, culminating in chronic infection
and destruction of the lung. The introduction of a nor-





) gene into the airway epithelium
through gene transfer is an attractive approach to cor-
recting the underlying defects in patients with cystic fi-
brosis. We tested the feasibility of gene therapy using









 complementary DNA in four logarithmically in-
creasing doses (estimated multiplicity of infection, 1, 10,
100, and 1000), or vehicle alone, was administered in a
randomized, blinded fashion to the nasal epithelium of 12
patients with cystic fibrosis. Gene transfer was quantitat-





 messenger RNA and by functional measure-
ments of transepithelial potential differences (PDs) to as-
sess abnormalities of ion transport specific to cystic fibro-
sis. The safety of this treatment was monitored by nasal





The adenoviral vector was detected in na-
sal-lavage fluid by culture, the polymerase chain reaction
(PCR), or both in a dose-dependent fashion for up to
eight days after vector administration. There was molec-
ular evidence of gene transfer by reverse-transcriptase
PCR assays or in situ hybridization in five of six patients
treated at the two highest doses. However, the percent-





1 percent), and measurement of PD across the ep-
ithelium revealed no significant restoration of chloride
transport or normalization of sodium transport. At the
lower doses of vector, there were no toxic effects. How-
ever, at the highest dose there was mucosal inflammation




In patients with cystic fibrosis, adenovi-




 gene did not
correct functional defects in nasal epithelium, and local
inflammatory responses limited the dose of adenovirus
that could be administered to overcome the inefficiency
of gene transfer. (N Engl J Med 1995;333:823-31.)
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YSTIC fibrosis is a recessive genetic disease caused
by mutations in the cystic fibrosis transmem-













 gene codes for a protein (CFTR) that plays








 result in abnormal secretions that
obstruct and ultimately damage epithelium in many ar-




The principal cause of death among patients with
cystic fibrosis is lung disease. Patients who are ho-




 gene have defec-









 in the airway
epithelium, which thicken airway secretions, impair
mucociliary clearance, and produce chronic bacterial









 gene do not have lung disease, which indi-





sufficient for normal defense of the lung. The transfer




 into all epithelial cells
affected by cystic fibrosis might be expected to correct
airway function.
We performed a double-blind, vehicle-controlled study
to assess the efficacy and safety of gene transfer to
treat disease of the airways associated with cystic fi-
brosis. An adenoviral vector was selected for this study
because of its reportedly high efficiency in gene trans-




 and preclinical studies of




 The study used a
dose-escalation protocol, in which the dose was de-




 by the esti-
mated multiplicity of infection (the number of infec-
tious adenoviral vectors delivered per airway epithelial
cell). We confined our treatment to the nasal epitheli-




 and cystic fibro-





 because of concern about safety
generated in preclinical studies in which lung tissue




 and also be-







This protocol was approved by the Committee for Protection of
the Rights of Human Subjects, the Recombinant Advisory Commit-
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 Additional information about the methods used is













6.9 percent of the
predicted value) and pancreatic exocrine insufficiency were studied




 The women had
negative pregnancy tests and used contraceptive methods. Informed






We used a replication-defective adenovirus serotype 5 vector with














 complementary DNA (cDNA). Three lots of the adenoviral
vector with particle:plaque-forming unit ratios ranging from 20:1 to
50:1 were produced by Good Manufacturing Practices at the Insti-









C) to the University of North Carolina at




 transduction by the
Western blot assay and for chloride secretion in vitro, and vector was
titered and shown to be efficacious (by the Western blot assay) after







The adenoviral vector was administered to four cohorts of three
patients each, in logarithmically increasing doses. The dose of a bi-
ologic vector is complex and may be described in terms of the con-
centration (in plaque-forming units per milliliter), the total dose (in
plaque-forming units), and the estimated number of vectors admin-
istered per epithelial cell (the estimated multiplicity of infection) (Ta-
ble 1). Two milliliters of vehicle or adenoviral vector was infused (for
30 minutes) under direct vision onto the inferior and medial surfaces

















) of the right nostril, with the subject
in a right lateral recumbent position. After treatment, the subject re-
mained in that position for an additional 20 minutes. The subject was
then repositioned in the left lateral recumbent position, and the left
nostril was treated with the alternative solution. Dosing-simulation




4 percent of the instilled solution remained
in the nose for 50 minutes. The identity of the instilled solutions was




We monitored for residual adenoviral vector in urine samples and
samples obtained with a swab from the nose, pharynx, and rectum




 and by a nested polymerase chain reac-
tion (PCR) using primers that amplify the L3 region of the adenovi-








We monitored symptoms, vital signs, and blood counts and in-
spected the nose visually each day. Chest radiography, blood-chem-
istry testing, and spirometry were performed at the beginning and
end of the study. Serum titers of adenoviral antibody were measured




 Nasal-lavage fluid was analyzed
daily for total cell counts (by hemocytometry), differential cell counts










 Six days after treatment, biopsy specimens from the inferior
turbinates were obtained, snap-frozen (in liquid nitrogen), and ana-




Efficacy of Gene Transfer
 
A reverse-transcriptase PCR assay of DNase-treated RNA from
scrape-biopsy specimens of nasal epithelium obtained 6 and 21 days















and untranslated viral sequences. In situ hybridization was per-




The functional efficacy of the vector treatment was assayed by
measuring the potential difference (PD), or voltage, across the nasal
epithelium on 3 separate days before treatment, then daily for up to




 The protocol measured
the basal PD (an index of sodium transport and mucosal integrity)
and indexes of sodium transport (the basal PD and the degree of in-







chloride permeability (the response to perfusion with a chloride-free
solution containing amiloride); cAMP-regulated (CFTR) secretion of






M] in the perfusate in
the presence of a chloride-free solution); and the capacity of the ep-






M] in the chlo-





was measured under the inferior turbinate (normal epithelium), the







The primary analysis of the effects of treatment on nasal PD used
a mixed model to fit repeated measures of the values obtained from
days 1 through 6 after treatment with vehicle or adenoviral vector
(the post-treatment values), using the base-line values (those ob-
tained from day 5 before treatment to the day of treatment) as pre-




 The secondary analysis compared
the mean base-line and post-treatment values by paired t-tests in
each cohort. Each analysis yielded the same outcome. Mean base-
line and post-treatment concentrations of inflammatory cells and me-
diators in nasal-lavage fluid were compared by paired t-tests. Scores
for inflammatory-cell infiltrates in the biopsy specimens treated with
vehicle were compared with those in the specimens treated with ad-
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 a substitution of proline for arginine at position 347.
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enoviral vector by paired t-tests. P values of less than 0.05 were con-




Vector was routinely cultured from samples obtained
20 minutes after dosing from nostrils dosed with ade-
noviral vector, and for up to four days after higher dos-
es (estimated multiplicity of infection, 100). One pa-
tient (Patient 11; estimated multiplicity of infection,
1000) had positive cultures from the vehicle-dosed
nostril on day 1 and from rectal samples obtained one
and two days after dosing. Additional data on individ-
ual patients are available from NAPS.*
PCR
Adenoviral-vector DNA was detected by PCR in
samples obtained from the dosed nostrils for two to
eight days after the administration of higher doses (es-
timated multiplicity of infection, 100). Vector DNA
was detected in the vehicle-dosed nostrils of two pa-
tients (Patients 4 and 10) one and four days, respec-
tively, after dosing, and from the pharynx of two pa-
tients (Patients 8 and 10) two days after dosing. In
urine samples, two patients (Patients 2 and 8) had
PCR products compatible with shedding of wild-type
adenoviral DNA (L3/E1a-positive, CFTR-negative).31,32
One patient (Patient 4) was positive by PCR for L3 but
not for E1a or CFTR on day 1 after treatment, making
it impossible to distinguish between wild-type adeno-
viral DNA and the degraded vector.
Molecular Assessment of Efficacy
Reverse-Transcriptase PCR Assay
Figure 1 shows the PCR product (210 base pairs
[bp]) of vector-expressed CFTR mRNA from inferior-
turbinate epithelium obtained six days after the admin-
istration of adenoviral vector; vector-specific products
were observed in several samples containing reverse
transcriptase. The summary data (Table 2) show that
only subjects who received the higher doses expressed
vector-specific mRNA. No subject had a positive re-
verse-transcriptase PCR product from samples ob-
tained three weeks after treatment. Samples from the
side of the nose on which vehicle was administered
were negative.
In Situ Hybridization
Biopsy specimens from the six subjects given the
higher doses (cohorts 3 and 4; estimated multiplicity of
infection, 100) were studied. Previous studies and the
positive controls used in this study (CFPAC cells) indi-
cated that in situ signals could be detected in single
cells probed for CFTR mRNA expressed in response to
the strong CB promoter.33 Approximately 14,000 cells
were examined in two sections from a biopsy speci-
men. No in situ signal was detected in specimens from
five of six subjects. In one patient who received the
highest dose (Patient 11), four patchy areas (i.e., con-
taining approximately 15 to 20 cells) of gene transfer
were detected; two were in regions of intact airway ep-
Figure 1. Reverse-Transcriptase PCR Assays for Adenoviral-
Vector–Mediated Expression of CFTR mRNA in the Nasal Epi-
— 210 bp
	 	 	 	 	 	










thelium of Patients with Cystic Fibrosis. 
Nasal epithelial cells were obtained by curette biopsy. RNA was
extracted, treated with DNase, and exposed to reverse trans-
criptase (	) or buffer (). A nested PCR was performed, and
the products were resolved on 3 percent NuSieve agarose gels
and stained with ethidium bromide. The results in five patients
who received various doses of vector (Patients 4 and 6 from co-
hort 2, Patients 7 and 9 from cohort 3, and Patient 12 from co-
hort 4) are shown. Viral DNA (from the adenoviral vector) and
water were added as a template for the positive and blank con-
trols, respectively. The 210-base-pair (bp) vector-specific PCR
product for CFTR mRNA is shown. M denotes the molecular-
weight marker.
*A vector-specific reverse-transcriptase PCR assay was used
to detect CFTR mRNA.
Table 2. Presence or Absence of Adenovi-
ral-Vector CFTR mRNA in Samples of Na-
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ithelium, and two were in areas of damage, including
expression in the submucosa. No signal was detected
in the nostrils treated with vector when the samples
were treated with RNase or studied with sense probes,
nor was an antisense signal detected in the nostrils
treated with vehicle.
Assessment of Biologic Efficacy by Measurements of PD
The measurements of PD under the inferior surface
of the turbinate (in normal ciliated epithelium) are
summarized below.
Basal PD
A total of 1440 PD measurements were made (Fig.
2). There was no change in basal PD among patients
who were exposed to vector at an estimated multiplic-
ity of infection of 1, 10, or 100 (cohorts 1, 2, and 3). In
contrast, the mean basal PD decreased by 15.11.6
mV after the administration of vector at the highest
dose (cohort 4, including Patients 10, 11, and 12; esti-
mated multiplicity of infection, 1000). There was no
significant change in the PD of epithelium treated with
vehicle in any cohort.
Inhibition by Amiloride
There was no change in the percentage of inhibi-
tion of the basal PD with amiloride, a sodium-chan-
nel blocker, after treatment with either vector or ve-
hicle in any cohort (inhibition in cohort 4, 69.52.7
percent before treatment with vector and 68.52.1
Figure 2. Basal Transepithelial Potential Difference (PD) before and after the Administration of Adenoviral Vector or Vehicle in Each
Cohort.
Individual measurements of the basal PD were made three times before the administration of adenoviral vector or vehicle (dashed
vertical lines, day 0) and serially for up to 21 days after treatment. The three patients in each cohort are designated by three symbols
(, , and ); the data for the nostrils in which vehicle was administered are designated by open symbols, and those for the nostrils
in which vector was administered are designated by solid symbols. Horizontal lines (dashed for vehicle, solid for vector) indicate the
mean values before treatment and on days 1 through 6 after treatment (before biopsy). Arrows indicate the time of biopsy. P
0.02
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percent afterward; estimated multiplicity of infection,
1000).
Basal Chloride Permeability
There were no systematic changes in PD after chloride
substitution, even in the highest-dose cohort (change in
PD in nostrils treated with vector in cohort 4, 5.80.7
mV before treatment and 4.50.4 mV afterward; in nos-
trils treated with vehicle, 4.70.6 and 4.50.5 mV, re-
spectively).
Isoproterenol-Regulated Chloride Secretion
We found no evidence of isoproterenol (cAMP)-
induced increases in PD (chloride secretion), even in
the highest-dose cohort (change in nostrils treated with
vector in cohort 4, 0.20.3 mV before treatment and
0.20.6 mV afterward; in nostrils treated with vehi-
cle, 0.80.4 and 0.30.3 mV, respectively).
Combined Response to Chloride Substitution and 
Isoproterenol
The change in nasal PD in amiloride-treated epithe-
lium in response to both chloride substitution and
treatment with isoproterenol best discriminates pa-
tients with cystic fibrosis from normal subjects29,34 (Fig.
3). The individual data points, relative to previously
published values from normal subjects29 (shaded area
in Fig. 3), are shown for each cohort. There were no
significant changes in PD, even in the highest-dose co-
hort (change in PD with vector in cohort 4, 4.90.3
Figure 3. Assay of Nasal PD to Determine the Extent of CFTR-Mediated Chloride Transport before and after the Administration of
Adenoviral Vector or Vehicle in Each Cohort.
The combined change in transepithelial PD in amiloride-pretreated nasal epithelium after chloride-free perfusion (with replacement
by gluconate) and the administration of isoproterenol is shown plotted against time in each cohort. The intervals measured, the time
of administration (vertical dashed lines), symbols denoting patients and type of treatment (open for vehicle, solid for vector), arrows
indicating the time of biopsy, and horizontal lines (dashed for vehicle, solid for vector) are as described in the legend to Figure 2.
The mean (SD) changes in the PD of normal subjects29 in response to the chloride-substitution–isoproterenol maneuver are shown
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mV before treatment and 2.01.7 mV afterward; with
vehicle, 4.61.6 and 3.81.4 mV, respectively).
ATP-Regulated Chloride Secretion
Large ATP-induced increases in PD, reflecting calci-
um-mediated chloride secretion, were detected in all
cohorts before treatment (change in PD with vehicle,
19.92.7 mV; with vector, 20.62.4 mV), and they
persisted after treatment (20.82.3 and 18.72.4
mV, respectively).
Data similar to those given above for normal epithe-
lium were obtained in each cohort for measurements of
PD on the medial surface of the inferior turbinate
(metaplastic epithelium).
Safety
No patient had significant changes in vital signs,
complete blood count, blood chemistry, chest radio-
graphs, or results of spirometric analysis. No patient
receiving doses of adenoviral vector with an estimated
multiplicity of infection of 1, 10, or 100 (cohorts 1, 2,
and 3) had local symptoms or signs. Two patients (Pa-
tients 10 and 12) in cohort 4 (the highest-dose group)
had symptoms and signs of toxic effects within 12 to
24 hours of the administration of the dose. One patient
(Patient 10) had an earache and an inflamed tympanic
membrane; the other (Patient 12) had jaw pain and
mandibular-angle (nodal) tenderness; these symptoms
were all ipsilateral to the site of administration of vec-
tor. Visual inspection by an ear, nose, and throat spe-
cialist who was unaware of the dosing schedule and the
symptoms of the patients revealed unilateral indura-
tion of the nasal mucosa and increases in mucosal sen-
sitivity and secretions that were confined to the nostril
treated with vector. Maximal symptoms and signs oc-
curred after 48 to 96 hours, and there was complete
resolution within three weeks. Further information on
individual patients is available from NAPS.*
Nasal Lavage and Measurements of Cells and Cytokines
No difference in the total cell count or in the quan-
tity of interleukin-1b, interleukin-6, interleukin-8, and
interleukin-10 in nasal-lavage fluid was noted on days
1 through 6 after the administration of vector or vehi-
cle in any cohort. The nostrils treated with vector in
the highest-dose cohort had a greater increase in the
total number of cells, neutrophils, interleukin-6, and
interleukin-8 in response to the nasal biopsy than did
the nostrils treated with vehicle, suggesting that the
adenoviral vector primed the epithelium for an inflam-
matory response.
Albumin in Nasal-Lavage Fluid
There was no change in the albumin concentration
in nasal-lavage fluid in Patients 1 through 9 (cohorts 1,
2, and 3) after the administration of either vector or
vehicle on days 1 through 6, as compared with the
base-line values (Fig. 4). In contrast, in the highest-
dose cohort (cohort 4), the albumin concentration dou-
bled in the nostrils treated with vector, but not in those
treated with vehicle. This increase was approximately
threefold in the two symptomatic patients (Patients 10
and 12).
Histopathological Analysis of Nasal-Biopsy Specimens
There was no difference in the number of inflam-
matory cells in the epithelium or submucosa between
the biopsy specimens from the nostrils treated with ad-
enoviral vector and those treated with vehicle in any
cohort.
Serum Antibodies to Adenovirus
One patient (Patient 10) in the highest-dose cohort
had an increase (from 1:80 to 1:1280) in the titer of
neutralizing antibody 21 days after the administration
of the vector.
DISCUSSION
In this double-blinded, vehicle-controlled trial of ad-
enoviral vector in patients with cystic fibrosis, we
found molecular evidence of low-efficiency gene trans-
*See NAPS document no. 05245 for seven pages of supplementary material.
Order from NAPS c/o Microfiche Publications, P.O. Box 3513, Grand Central
Station, New York, NY 10163-3513. Remit in advance (in U.S. funds only) $7.75
for photocopies or $4 for microfiche. Outside the U.S. and Canada, add postage
of $4.50 ($1.75 for microfiche postage). There is a $15 invoicing charge for all
orders filled before payment.
Figure 4. Mean (SE) Change from Base Line in the Albumin
Content of Nasal-Lavage Fluid during the Six Days after the Ad-
ministration of Vehicle (Open Bars) or Vector (Solid Bars), Ex-
pressed as the Percentage of Change from the Values before
Treatment.
The values for cohorts 1, 2, and 3 (Patients 1 through 9) and
cohort 4 (Patients 10, 11, and 12) are shown separately. The two
patients (Patients 10 and 12) in cohort 4 who had signs and
symptoms of nasal inflammation or damage are shown so that
their data may be compared with the mean data for cohort 4.
The base-line levels of albumin in nasal-lavage fluid in each
group shown were as follows: cohorts 1, 2, and 3, 12.0 mg per
milliliter in the vehicle-treated nostril and 12.2 mg per milliliter in
the vector-treated nostril; cohort 4, 2.4 and 6.4 mg per milliliter;






































1 through 9 10, 11, and 12
The New England Journal of Medicine 
Downloaded from nejm.org on September 8, 2020. For personal use only. No other uses without permission. 
 Copyright © 1995 Massachusetts Medical Society. All rights reserved. 
Vol. 333 No. 13 ADENOVIRAL-VECTOR–MEDIATED GENE TRANSFER FOR CYSTIC FIBROSIS 829
fer and expression of the normal CFTR mRNA in na-
sal epithelium, but there was no significant functional
correction of abnormalities in ion transport. The ab-
sence of adenoviral-vector tropism for surface colum-
nar cells,35 which normally express CFTR,36 explains
this failure. This problem cannot be overcome by sim-
ply increasing the dose of the vector, because the high-
est dose we used (with an estimated multiplicity of in-
fection of 1000) was associated with inflammatory
responses in two of three patients; in addition, studies
in animals indicate a wide spectrum of toxic effects at
higher doses.18-20
Careful attention was paid to the design, production,
and administration of the vector we used. With its
strong promoter, this vector was completely effective in
correcting cystic fibrosis–associated defects of chlo-
ride35 and sodium transport in the airway epithelium
in vitro.37 Three separate lots of vector were pro-
duced21,38 and tested for the titer and for the efficacy of
CFTR gene transfer at two independent sites before
their use. The adequacy of vector administration and
the viability of the vector were confirmed by its detec-
tion in the nostril treated with vector up to eight days
after the administration of the dose.
Two outcome variables were measured with respect
to efficacy and were grouped on the basis of dosage. In
the two lower-dose cohorts (cohorts 1 and 2; estimated
multiplicity of infection, 1 and 10, respectively), we
found little evidence of adenoviral-vector–mediated
gene transfer. Only one of six patients was positive for
gene transfer by the reverse-transcriptase PCR assay.
This assay is sensitive to as few as 5 cells expressing
vector CFTR mRNA among 500,000 cells not express-
ing this mRNA (0.001 percent); thus, the negative
PCR data in these cohorts indicated that virtually no
gene transfer occurred.39 The lack of functional correc-
tion of PD is consistent with this conclusion.
In the two higher-dose cohorts (cohorts 3 and 4; es-
timated multiplicity of infection, 100 and 1000, respec-
tively), there was more evidence of gene transfer by
the reverse-transcriptase PCR assay (four of six pa-
tients were positive). However, in situ hybridization,
which is about one order of magnitude less sensitive
than the PCR assay, detected expression in only one of
these six patients, and the percentage of epithelial cells
expressing CFTR mRNA in this one patient was low
(less than 1 percent of the total number). Previous
studies have shown that CFTR expression in 3 to 6 per-
cent of the cells in the cystic fibrosis epithelium is re-
quired to correct the defect in chloride secretion.35,40
The PD protocols that are sensitive measures of CFTR-
mediated chloride transport (e.g., the combined re-
sponse to chloride substitution and isoproterenol) de-
tected no systematic evidence of gene transfer, a finding
consistent with an efficiency of gene transfer of less
than 1 percent (Fig. 3). 
Three data points slightly above the range for cystic
fibrosis in the highest-dose cohort could reflect patchy
gene transfer or nonspecific effects of isoproterenol to
activate a calcium-regulated chloride pathway in in-
flamed tissues. The relation between the efficiency of
correction and the restoration of sodium transport is
different from that for chloride, with virtually all cells
requiring functional correction in order for the normal-
ization of sodium transport to occur. There was no
change in the percentage of inhibition of PD by amil-
oride in cohorts 3 and 4 to suggest a correction of so-
dium transport. Thus, in these cohorts vector-mediat-
ed gene transfer was detected, but its efficiency was too
low for either the chloride or the sodium-transport de-
fect associated with cystic fibrosis to be corrected.
No evidence of systemic toxic effects was noted in
any patient, and no local toxic effects were noted in the
cohorts receiving the three lowest doses. However, two
of the three patients in the highest-dose cohort had
symptoms and signs of local toxic effects in the mu-
cosa, reduced basal PDs, and an increased flux of al-
bumin into the fluid subsequently obtained by lavage
from the nostrils treated with vector — observations
consistent with epithelial damage.29,41,42 The syndrome
was not associated with increased numbers of white
cells or concentrations of cytokines in nasal-lavage flu-
id or with the cellular infiltrates associated with more
chronic toxic effects (lasting 3 to 21 days) that have
been identified in studies in animals.18-20 The rapid on-
set of the syndrome, like the severe pulmonary inflam-
matory reaction to Ad-CFTR, a similar adenoviral vec-
tor, in a patient described by Crystal et al.,15 coupled
with recent studies in animals,43 suggests a neurogenic
inflammatory cause.
Three observations were made that may pertain to
the safety of the vector we used. First, there was dis-
semination of the vector — for example, to the phar-
ynx and stool — at higher doses. Second, we detected
vector DNA in the nasal cavity for up to eight days.
The precise location of the vector in the epithelium is
not known, and therefore the possibility of transmis-
sion or recombination of vector with wild-type adeno-
virus cannot be discounted.21,44 Finally, we observed an
increase in the serum antibody titer in one patient re-
ceiving the highest dose of vector, which may have im-
plications for the safety of the vector (e.g., enhanced
immunologic responses on subsequent treatment with
vector), implications for the efficacy of repeated ad-
ministration of vector, or both.19
Two unblinded trials of Ad-CFTR in patients with
cystic fibrosis have been reported. We could not con-
firm the correction of the cystic fibrosis–associated na-
sal defect of chloride transport reported by Zabner et
al.14 Our study paralleled their study with respect to
the site of deposition, and we used a vector with a
stronger promoter and used that vector in higher con-
centrations (1.5 to 3 logs). The discrepancy probably
relates to the PD protocols used to measure efficacy.
The protocol used by Zabner et al. does not readily dis-
criminate between patients with cystic fibrosis and
normal subjects, making it difficult to interpret the
results. The chloride-free PD protocols used in this
study are highly sensitive in such discrimination29,34
and can detect full or even partial correction of chlo-
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ride transport. This discrepancy highlights the need
for standardized PD protocols and for complementary
molecular and morphologic methods of assessing gene
transfer.
Crystal et al.15 reported no quantitative nasal bio-
electric data, but they did report positive results of im-
munocytochemical analysis for CFTR in one of four
patients after bronchial brushing of a region that had
received transbronchoscopic doses of vector. The evi-
dence of transduction in bronchial cells may possibly
reflect an increased efficiency of gene transfer in lower
airway epithelium as compared with nasal epithelium,
as has been reported in rodents.12,18 Alternatively, dam-
age to airway epithelium can substantially enhance
gene transfer by abrading the relevant target cells (i.e.,
the surface columnar cells) and exposing the vector to
basal cells, which are more easily transduced but do
not normally express CFTR.35 Thus, data pertaining
to transduced epithelium from previously traumatized
areas may not be representative of gene transfer to in-
tact, undamaged epithelium, such as that treated in
our study.
In summary, adenoviral-vector–mediated gene trans-
fer to nasal epithelium affected by cystic fibrosis is in-
efficient. One potential strategy to overcome this prob-
lem would be to target adenoviral vectors to basal
cells. Another would involve attempting to differentiate
basal cells into columnar cells. A third would be to
modify the vector itself so that it becomes tropic for
columnar cells. If the nasal epithelium is typical of all
human airway regions with respect to the observed in-
efficiency of adenoviral-vector–mediated gene transfer,
it would appear prudent also to accelerate the develop-
ment of alternative vectors,45 or to modify the adeno-
viral vectors, if gene transfer is to be successful in
treating lungs in patients with cystic fibrosis.
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C.-H. Wong, and I. Wortman for expert technical assistance, to
L. Dudus and H. Ye for assistance with the in situ hybridization stud-
ies, to P. Noone and W. Bennett for assistance with the dosing-simu-
lation studies, to K. Kozarsky for assistance in the serologic testing
for adenovirus by the Western blot assay, to L. Brown for editorial
assistance, to the nursing staff of the General Clinical Research Cen-
ter for expert patient care, and to the patients who participated in
this challenging study.
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